LIGHT initiative - Phase 1

Desmond Hsu



SEPTEMBER 8-11, 2019 | BARBICAN CENTRE

SPONSORED BY:



IN PARTNERSHIP WITH:



LIGHT initiative Phase 1

Integration of opt-out HIV tests in primary care Glandular fever serology ordersets - simple, effective and sustainable increase in HIV testing in line with UK & European guidelines

DTS Hsu¹, M Ruf², G Leong³ and S Douthwaite¹ on behalf of the LIGHT steering group 1 Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK; 2 Medical Department, Gilead Sciences, UK, 3 Public Health England, UK

LIGHT: London Initiative for Glandular fever HIV Testing



🖿 🌠 GILEAD

Disclosures

- This project has been supported through an Association of the British Pharmaceutical Industry (APBI) joint working initiative with Gilead Sciences Ltd.
- National Health Service (NHS) and Public Health England (PHE) partners contributed independent expertise and skills in their own professional capacity without additional financial support.
- Gilead provided technical expertise, project management and funding for electronic software modification and additional HIV testing.
- Data generation and analysis were done independently by NHS and PHE partners.
- Content, conclusions and recommendations were agreed by consensus by all authors.

Anonymous seroprevalence survey was funded by NHS Lambeth Primary Care Trust (2009)



Self-resolving syndrome

- Non-specific: fever, myalgia, headache & rash
- typically 2 to 5 weeks after infection in 40-90% of individuals ^{2, 3}
- *"Glandular fever-like illness/Mononucleosis-like illness" (GFLI)*

Often the only clinical manifestation before more advanced disease many years later -

> a diagnostic opportunity

1. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951–959.

2. UK National Guidelines for HIV Testing. 2008. British HIV Association, British Association of Sexual Health and HIV, British Infection Society, 2008. Available at www.bashh.org/documents/1838 3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on May 01, 2014).



Background

GFLI is a **recognised HIV indicator condition** in European¹ & UK² guidelines

Historically...

- A 'Glandular Fever Screen' (**GFS**) = EBV & CMV & Toxoplasmosis
- HIV testing required additional test ordering
- Concomitant HIV testing in patients who receive GFS in primary care has been poor in our area (anonymous seroprevalence survey 2010: 11.4%)³

- 1. Public Health guidance on HIV, hepatitis B and C testing in the EU/EEA. European Centre for Disease Prevention and Control (ECDC). 2018. Available at https://ecdc.europa.eu/sites/portal/files/documents/hiv-hep-testing-guidance_0.pdf (accessed on 8 August 2019).
- HIV testing: Increasing uptake among people who may have undiagnosed HIV. NICE Guidelines. 2016. Available at www.nice.org.uk/guidance/ng60 (accessed 21 August 2019).
 Hsu DTS, et al. Diagnosing HIV infection in patients presenting with glandular fever-like illness in primary care: are we missing primary HIV infection? *HIV Medicine* Jan;14(1):60-3. 2013.

Diagnosed HIV prevalence per 1,000 population aged 15-59 years accessing HIV care, 2017





Aim

To evaluate effectiveness of *modification of electronically requested serology ordersets* to increase opt-out HIV testing for recognised HIV indicator condition in primary care (phase 1)

Intervention

Pre-LIGHT: GFS requested by either electronic (e-Original) or Paper-based requesting (Paper)

LIGHT intervention: July 2014

- e-Modified replaces e-Original
- e-Original remained available via archive

Paper	CMV EBV Toxo
e-Original	CMV EBV Toxo
e-Modified	e-Original including opt-out HIV test for patients >16yrs





Results

Time period	Test ordering	GFS tests ordered	Concomitant HIV tests ordered (95% CI)		Positive HIV tests	No. of Male Positive HIV
Pre- LIGHT Jan - Dec2013 (12 months)	e-Orders & Paper	880	295	33% (30 – 38%)	3 (1.0%)	-
LIGHT Dec 2015 - Aug 2017 (20 months*)	e-Orders	1,857	1,442	78% (74 – 82%)	10 (0.7%)	9 (90%)
	Paper (control)	485	136	28% (24 – 33%)	1 (0.7%)	1

Key points

~ 135% (78%/33%) sustainable increase in guidelines recommended HIV tests

LIGHT (20 month sample): HIV test positivity 0.7% (11/1578)

- 64% (7/11): new diagnoses
- 43% (3/7): clinical and/or laboratory evidence of recently acquired HIV*
- Simple, sustainable and low-cost intervention:

<£8,000 one-off (2014) for laboratory requesting IT modification covering 53 primary care practices

Limitations

- Real world service development project; no dedicated research staff
- Snapshot data: random 20 month period only
- No recording of reason for opting-out of HIV testing

Conclusions

- Our simple modification of electronic pathology requesting panel significantly and sustainably increased the rate of guideline recommended HIV tests
- This system-wide, replicable and low one-off cost intervention targets patients presenting with a recognised HIV indicator condition
- "Ebola-proof"

Next steps:

- NHS Lambeth & Southwark (King's College Hospital) independently initiated 2017¹
- Phase 2 expansion planning across NHS East London 2019²
- 1. Mark Zuckerman, Consultant Virologist, King's College Hospital, London
- 2. Chris Lovitt, Associate Director Public Health, Tower Hamlets, London